TD Asset Management Inc. cut its stake in TESARO Inc (NASDAQ:TSRO) by 7.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 88,902 shares of the biopharmaceutical company’s stock after selling 7,060 shares during the period. TD Asset Management Inc. owned 0.16% of TESARO worth $11,477,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Exane Derivatives bought a new stake in shares of TESARO during the third quarter worth approximately $106,000. Botty Investors LLC bought a new stake in shares of TESARO during the second quarter worth approximately $140,000. Nordea Investment Management AB bought a new stake in shares of TESARO during the second quarter worth approximately $167,000. Oppenheimer Asset Management Inc. raised its stake in shares of TESARO by 3,042.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 1,430 shares during the last quarter. Finally, Toronto Dominion Bank raised its stake in shares of TESARO by 244.6% during the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 1,130 shares during the last quarter.

In related news, SVP Martin H. Jr. Huber sold 592 shares of the stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $118.60, for a total transaction of $70,211.20. Following the completion of the transaction, the senior vice president now owns 6,943 shares in the company, valued at $823,439.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James O. Armitage sold 10,000 shares of the stock in a transaction on Monday, September 18th. The stock was sold at an average price of $117.13, for a total transaction of $1,171,300.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $1,171,300. The disclosure for this sale can be found here. Insiders have sold 21,525 shares of company stock valued at $2,716,431 in the last 90 days. 40.50% of the stock is currently owned by corporate insiders.

TSRO has been the subject of a number of recent research reports. Morgan Stanley reissued an “overweight” rating and set a $165.00 price target (down from $181.00) on shares of TESARO in a research note on Wednesday, November 8th. Cann reissued a “buy” rating and set a $199.00 price target on shares of TESARO in a research note on Friday, September 8th. Citigroup reissued a “buy” rating and set a $216.00 price target on shares of TESARO in a research note on Monday, September 11th. Zacks Investment Research downgraded shares of TESARO from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Finally, Wedbush reissued an “outperform” rating and set a $160.00 price target on shares of TESARO in a research note on Monday, September 11th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $159.39.

TESARO Inc (TSRO) opened at $85.16 on Friday. TESARO Inc has a 1-year low of $79.03 and a 1-year high of $192.94. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34.

TESARO (NASDAQ:TSRO) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. The company had revenue of $142.77 million during the quarter, compared to analysts’ expectations of $130.57 million. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The business’s quarterly revenue was up 740.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.72) earnings per share. equities research analysts expect that TESARO Inc will post -8.16 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “TESARO Inc (TSRO) Shares Sold by TD Asset Management Inc.” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/tesaro-inc-tsro-shares-sold-by-td-asset-management-inc/1740798.html.

TESARO Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO Inc (NASDAQ:TSRO).

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.